{"product_id":"irtc-vrio-analysis","title":"iRhythm Technologies, Inc. (IRTC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets behind iRhythm Technologies, Inc. (IRTC)'s market position with this concise VRIO Analysis. We distill whether its current assets are truly Valuable, Rare, Inimitable, and Organized to forge a sustainable competitive advantage, as summarized in \u0026amp;O4\u0026amp;. Read on immediately to see the strategic strengths - and potential weaknesses - that define this business's path forward.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: Proprietary AI\/Algorithm Suite (ZEUS)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core engine of iRhythm Technologies, Inc.'s moat: the ZEUS (Zio ECG Utilization Software) platform. Honestly, this AI suite is where the real value is locked up, not just in the patch itself. It’s the difference between collecting data and actually diagnosing something useful, fast.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Clinically Actionable Insights\u003c\/h3\u003e\n\u003cp\u003eThe value proposition here is crystal clear: better diagnosis rates mean better patient outcomes and lower downstream costs. The ZEUS system, which uses an FDA-cleared AI algorithm, distills data from millions of heartbeats into actionable reports. We saw this superiority reinforced in 2025 data presented at HRS2025 from the AVALON study, which looked at commercially insured patients. The Zio Long-Term Continuous Monitoring (LTCM) service, powered by ZEUS, resulted in a 26.5% rate of new arrhythmia diagnosis within the first 90 days. That significantly outpaces the 18.4% seen with non-iRhythm LTCM devices and the 14.7% for traditional Holter monitors. The physician agreement rate on the end-of-wear report is a staggering 99%. That’s precision you can bank on.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: The Data Advantage\u003c\/h3\u003e\n\u003cp\u003eWhat makes ZEUS rare isn't just the code; it’s the fuel for that code. The algorithm is trained on a massive, proprietary dataset that competitors simply cannot replicate quickly. As of late 2025, iRhythm’s evidence base is built on insights derived from over 2 billion hours of curated heartbeat data and nearly 12 million patient reports since inception. This sheer volume of labeled, real-world cardiac data is the barrier to entry. It’s defintely not something a startup can whip up in a weekend.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Cost and Time to Replicate\u003c\/h3\u003e\n\u003cp\u003eDirect imitation is tough because the algorithm's performance is directly tied to that proprietary, ever-growing dataset. You can copy the software architecture, sure, but without the billions of hours of labeled data to train it on, the performance won't match. The company is actively working on next-generation submissions, like delaying the next-gen Zio MCT submission until the third quarter of 2025, showing they are investing heavily in maintaining this lead. The cost and time required to build a comparable dataset and achieve the same clinical validation - which is crucial for adoption - make this resource highly inimitable in the near term.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Regulatory and Financial Alignment\u003c\/h3\u003e\n\u003cp\u003eiRhythm Technologies is showing strong organizational alignment by actively managing its regulatory pathway and investing in the platform. They secured two 510(k) clearances for the Zio AT device in late 2024, addressing prior FDA concerns, and are submitting next-gen updates. Financially, the organization is scaling effectively; they raised their full-year 2025 revenue guidance to between $735M and $740M, with Q3 2025 revenue hitting $192.9M, a 30.7% jump year-over-year. Plus, they held $565.2M in unrestricted cash as of September 30, 2025, providing the capital runway to continue developing and defending this AI advantage.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes (Higher diagnostic yield: \u003cstrong\u003e26.5%\u003c\/strong\u003e vs. Holter's \u003cstrong\u003e14.7%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity or Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes (Trained on over \u003cstrong\u003e2 billion hours\u003c\/strong\u003e of proprietary data)\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh (Data network effect and clinical validation cost)\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eHigh (Active regulatory remediation, strong revenue growth: \u003cstrong\u003e$735M–$740M\u003c\/strong\u003e guidance for \u003cstrong\u003e2025\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eThe combination of the algorithm and the data it generates creates a powerful, self-reinforcing moat.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe combination of the algorithm and the data it generates creates a powerful, self-reinforcing moat. This is the engine that keeps them ahead.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft the Q4 2025 expense forecast incorporating the raised full-year revenue guidance by Wednesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: Clinical Evidence \u0026amp; Real-World Data Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Evidence \u0026amp; Real-World Data Asset\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides superior clinical validation, showing Zio LTCM is associated with higher diagnosis rates and lower cardiovascular event likelihood than alternatives.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare. Having published data across over \u003cstrong\u003e125\u003c\/strong\u003e manuscripts and insights from over \u003cstrong\u003e2 billion\u003c\/strong\u003e hours of curated data is a significant asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors cannot easily replicate the volume and quality of real-world evidence iRhythm has generated over years of use.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are actively presenting new data at major conferences like AHA 2025, showing a commitment to evidence-based adoption. Data presented at AHA 2025 included insights from over \u003cstrong\u003e742,000\u003c\/strong\u003e patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This evidence base directly influences physician behavior and payer decisions, which is hard to overcome.\u003c\/p\u003e\n\n\u003cp\u003eThe clinical superiority is quantified in comparative studies:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eZio LTCM was associated with the highest diagnostic yield in Medicare beneficiaries, with an encounter diagnosis of an arrhythmia within the first 90 days of \u003cstrong\u003e33.8%\u003c\/strong\u003e, compared to Holter at \u003cstrong\u003e22.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eZio LTCM was \u003cstrong\u003e1.95\u003c\/strong\u003e times more likely to achieve a clinical arrhythmia encounter diagnosis compared to Holter in the CAMELOT study.\u003c\/li\u003e\n\u003cli\u003eIn the AVALON study, Zio LTCM was \u003cstrong\u003e1.56\u003c\/strong\u003e times more likely to have a new arrhythmia encounter diagnosis within 90-days compared to non-iRhythm LTCM services.\u003c\/li\u003e\n\u003cli\u003eZio LTCM service was associated with the lowest likelihood of retesting compared to all other monitoring services.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eComparison Metric (vs. Zio LTCM)\u003c\/th\u003e\n\u003cth\u003eNon-iRhythm LTCM\u003c\/th\u003e\n\u003cth\u003eHolter\u003c\/th\u003e\n\u003cth\u003eExternal Ambulatory Event Monitoring (AEM)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLikelihood of Retest (Odds Ratio)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3.7\u003c\/strong\u003e times more likely\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.4\u003c\/strong\u003e times more likely\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4.3\u003c\/strong\u003e times more likely\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLikelihood of 90-Day Arrhythmia Encounter Diagnosis (Odds Ratio)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0.64\u003c\/strong\u003e times (i.e., 1.56x more likely for Zio)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0.51\u003c\/strong\u003e times (i.e., 1.95x more likely for Zio)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0.23\u003c\/strong\u003e times (i.e., 4.3x more likely for Zio)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinancial performance supporting the asset's value:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThird Quarter 2025 Revenue: \u003cstrong\u003e$192.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThird Quarter 2025 Gross Margin: \u003cstrong\u003e71.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 Revenue Guidance: Between \u003cstrong\u003e$735 million\u003c\/strong\u003e to \u003cstrong\u003e$740 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUnrestricted Cash, Cash Equivalents, and Marketable Securities (as of September 30, 2025): \u003cstrong\u003e$565.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThird Quarter 2025 Adjusted Net Loss: \u003cstrong\u003e$2.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: Zio Wearable Biosensor Technology \u0026amp; IP Portfolio\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eZio Wearable Biosensor Technology \u0026amp; IP Portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment Detail\u003c\/th\u003e\n\u003cth\u003eSupporting Real-Life Data\/Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eLong-wear, patient-compliant, high-quality data capture.\u003c\/td\u003e\n\u003ctd\u003eWear time up to \u003cstrong\u003e14 days\u003c\/strong\u003e. \u003cstrong\u003e99%\u003c\/strong\u003e physician agreement with end-of-wear reports. \u003cstrong\u003eQ3 2025\u003c\/strong\u003e Revenue: \u003cstrong\u003e$192.9 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eSpecific form factor, wear time, and IP protection.\u003c\/td\u003e\n\u003ctd\u003eCovered by one or more U.S. and international patents\/applications. U.S. Patents cited include 8,150,502, 8,160,682, 8,244,335, 8,560,046, and 8,538,503.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eProtected by numerous patents, but core technology can be designed around.\u003c\/td\u003e\n\u003ctd\u003eMultiple patents granted in 2024 (e.g., Patent No. 11998342) and 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eFocus on continuous improvement and regulatory compliance.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eQ3 2025\u003c\/strong\u003e Gross Margin: \u003cstrong\u003e71.1%\u003c\/strong\u003e. Next-gen Zio MCT FDA submission delayed to \u003cstrong\u003eQ3 2025\u003c\/strong\u003e for commercial launch in 2026.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe Zio patch is a simple, long-wear (up to \u003cstrong\u003e14 days\u003c\/strong\u003e), patient-compliant device that captures high-quality, continuous ECG data. The monitoring service combines the patch with an FDA-cleared, deep-learned algorithm verified by QCTs to generate reports with \u003cstrong\u003e99%\u003c\/strong\u003e physician agreement. The platform achieved one million patients registered for the Zio monitor as of Q3 2024. The Q3 2025 revenue reached \u003cstrong\u003e$192.9 million\u003c\/strong\u003e, a \u003cstrong\u003e30.7%\u003c\/strong\u003e increase year-over-year.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eWhile other patches exist, the specific form factor, wear time, and IP protection around the Zio monitor are unique. The technology is covered by or for use under one or more international patents or international patent applications. Specific U.S. Patents cited include 8,150,502, 8,160,682, 8,244,335, 8,560,046, and 8,538,503. The Zio AT device is intended to capture and transmit symptomatic and asymptomatic cardiac events and record continuous electrocardiogram (ECG) data for long-term monitoring.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe core technology is protected by numerous U.S. and international patents, but competitors can design around some aspects. New patents continue to be granted, such as Patent No. 11998342 granted on June 4, 2024. The Zio AT patch is a single-use ECG monitor applied to the patient's chest, worn for up to 14 days without any required patient interaction for maintenance.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe company is focused on continuous improvement, evidenced by the Q3 2025 gross margin of \u003cstrong\u003e71.1%\u003c\/strong\u003e, a 230-basis point improvement compared to Q3 2024. The CEO indicated a delay of the FDA submission for the next-generation Zio MCT device until Q3 2025, with a commercial launch expected in 2026. Full year 2025 revenue guidance is projected between $735 million to $740 million.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary to Sustained. Patents offer temporary protection, including U.S. Patent No. 11925469 granted in March 2024. The integrated system performance, supported by 99% physician agreement, is the real barrier. The company reported $565.2 million in unrestricted cash, cash equivalents, and marketable securities as of September 30, 2025.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eZio AT Indications for Use: Intended for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety.\u003c\/li\u003e\n\u003cli\u003eZio AT is \u003cstrong\u003enot\u003c\/strong\u003e intended for use on critical care patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: Brand Trust and Physician Confidence\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A \u003cstrong\u003e99%\u003c\/strong\u003e physician agreement rate on end-of-wear reports translates directly into trust, adoption, and reduced liability concerns for clinicians.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare. Such a high level of clinical consensus in diagnostics is not common in medical technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Trust is built over time through consistent performance and clinical validation, not just by launching a product.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The entire service model is built around delivering a report that physicians can confidently act upon, which is a core organizational focus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Brand equity and deep-seated clinical trust are very difficult for newcomers to erode quickly.\u003c\/p\u003e\n\u003cp\u003eKey statistical and operational metrics underpinning this confidence include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician Confidence\u003c\/td\u003e\n\u003ctd\u003ePhysician Agreement Rate on End-of-Wear Reports\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Scale\/Experience\u003c\/td\u003e\n\u003ctd\u003eTotal Patient Reports Posted Since Inception\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e10 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Scale\/Experience\u003c\/td\u003e\n\u003ctd\u003eTotal Curated Heartbeat Hours\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Penetration (LTCM)\u003c\/td\u003e\n\u003ctd\u003eiRhythm Market Share in LTCM Segment\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e70%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdoption (Next-Gen Zio Monitor)\u003c\/td\u003e\n\u003ctd\u003eU.S. Zio Monitor Registrations (Since Sept 2023 Launch)\u003c\/td\u003e\n\u003ctd\u003eReached \u003cstrong\u003e1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdoption (Next-Gen Zio Monitor)\u003c\/td\u003e\n\u003ctd\u003ePercentage of U.S. LTCM Registrations from Next-Gen Zio Monitor (as of Sept 2024)\u003c\/td\u003e\n\u003ctd\u003eAlmost \u003cstrong\u003e70%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Performance (Next-Gen vs. Prior)\u003c\/td\u003e\n\u003ctd\u003eEarly Wear Termination (\u0026lt; 48 hours) for Zio Monitor\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Performance (Next-Gen vs. Prior)\u003c\/td\u003e\n\u003ctd\u003eEarly Wear Termination (\u0026lt; 48 hours) for Zio XT\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther evidence of organizational focus and clinical validation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eZio penetration within cardiology at top 50 health systems was nearly \u003cstrong\u003e42%\u003c\/strong\u003e (as of September 2022).\u003c\/li\u003e\n\u003cli\u003eAnnual Zio prescriptions per cardiologist grew \u003cstrong\u003e31%\u003c\/strong\u003e since 2019 (as of September 2022).\u003c\/li\u003e\n\u003cli\u003eThe Zio LTCM service was associated with the highest diagnostic yield compared to other Ambulatory Cardiac Monitoring (ACM) modalities in Medicare beneficiaries (CAMELOT study).\u003c\/li\u003e\n\u003cli\u003eThe Zio LTCM service was associated with a lower probability of repeat testing compared to other ACMs in commercially insured patients (AVALON study).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: Scalable Cloud-Based Data Analytics Platform\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe platform supports the processing of data from over 10 million patient reports since inception as of the first quarter of 2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nMedium.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe platform's leverage is evidenced by the third quarter of 2025 gross margin of 71.1%.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary.\n\u003c\/p\u003e\n\u003cp\u003e\nKey Financial Metrics Supporting Platform Scale and Leverage:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Guidance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$192.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$735 million to $740 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.25% to 8.75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnrestricted Cash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$565.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nPlatform-Relevant Data Points:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross profit for Q3 2025 was \u003cstrong\u003e$137.1 million\u003c\/strong\u003e, up \u003cstrong\u003e35.1%\u003c\/strong\u003e from Q3 2024.\u003c\/li\u003e\n\u003cli\u003eGross margin improvement of \u003cstrong\u003e230-basis points\u003c\/strong\u003e from Q3 2024 to Q3 2025.\u003c\/li\u003e\n\u003cli\u003eFull year 2025 revenue guidance represents an increase from 2024 revenue of \u003cstrong\u003e$591.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross margin in Q1 2025 was \u003cstrong\u003e68.8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: Market Leadership in U.S. LTCM Segment\n\u003c\/h2\u003e\n\n\u003cp\u003e\nThe U.S. Long-Term Continuous Monitoring (LTCM) segment is central to iRhythm's current financial performance and future projections.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Metric\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eNew arrhythmia diagnosis rate of \u003cstrong\u003e26.5%\u003c\/strong\u003e (Zio LTCM vs. \u003cstrong\u003e14.7%\u003c\/strong\u003e for Holter)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eRepresents almost \u003cstrong\u003e70%\u003c\/strong\u003e of iRhythm's LTCM registrations in the U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eMarket size estimated at \u003cstrong\u003e$5.8 billion\u003c\/strong\u003e in 2022, with a \u003cstrong\u003e10.4%\u003c\/strong\u003e CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eProjected 2024 Revenue: \u003cstrong\u003e$582.5 million\u003c\/strong\u003e to \u003cstrong\u003e$587.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Gross Margin: \u003cstrong\u003e68.8%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\nThe value is evidenced by strong financial results driven by the core business.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2024 Revenue: \u003cstrong\u003e$147.5 million\u003c\/strong\u003e, an \u003cstrong\u003e18%\u003c\/strong\u003e increase compared to Q3 2023.\u003c\/li\u003e\n\u003cli\u003eQ3 2024 Gross Margin: \u003cstrong\u003e68.8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUnrestricted cash, cash equivalents and marketable securities as of September 30, 2024: \u003cstrong\u003e$522.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\nDominant position in a specialized, high-growth area.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Zio LTCM monitor and service represent almost \u003cstrong\u003e70%\u003c\/strong\u003e of iRhythm's LTCM registrations in the United States as of September 2024.\u003c\/li\u003e\n\u003cli\u003eZio LTCM service demonstrated a new arrhythmia diagnosis rate of \u003cstrong\u003e26.5%\u003c\/strong\u003e in a study cohort, higher than non-iRhythm LTCMs at \u003cstrong\u003e18.4%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\nBarriers to entry are substantial given the established installed base and clinical workflow integration.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe overall ambulatory cardiac monitoring market size was estimated at \u003cstrong\u003e$5.8 billion\u003c\/strong\u003e in 2022.\u003c\/li\u003e\n\u003cli\u003eThe market is projected to grow at a CAGR of \u003cstrong\u003e10.4%\u003c\/strong\u003e from 2023 to 2030.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\nThe company's structure and guidance are aligned with leveraging this market position.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e2024 Full Year Revenue Guidance range: approximately \u003cstrong\u003e$582.5 million\u003c\/strong\u003e to \u003cstrong\u003e$587.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2024 Full Year Gross Margin Guidance range: \u003cstrong\u003e68.5%\u003c\/strong\u003e to \u003cstrong\u003e69.0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\nMarket leadership translates into tangible operational and financial benefits.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2024 Gross Margin of \u003cstrong\u003e68.8%\u003c\/strong\u003e, an increase of \u003cstrong\u003e260-basis points\u003c\/strong\u003e compared to Q3 2023.\u003c\/li\u003e\n\u003cli\u003eZio LTCM service was associated with a \u003cstrong\u003e1.95 times\u003c\/strong\u003e lower adjusted odds of retesting within 180 days compared to all non-iRhythm LTCMs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: Zio AT\/MCT Service Offering\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eZio AT\/MCT Service Offering\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: The Zio AT service offers Mobile Cardiac Telemetry (MCT), a higher-tier, more immediate monitoring service that captures a higher blended cost per unit.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe increased Zio AT product mix contributed to a higher blended cost per unit, as noted when Q3 2025 Gross Margin of \u003cstrong\u003e71.1%\u003c\/strong\u003e was achieved, partially offset by this mix effect. The Zio AT device enables iRhythm’s Mobile Cardiac Telemetry (MCT) monitoring service. In a study cohort that included \u003cstrong\u003e23%\u003c\/strong\u003e mobile cardiac telemetry (MCT), Zio LTCM (which includes Zio AT) was associated with a higher diagnostic yield than MCT. \u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Comparison\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZio AT Product Mix Impact\u003c\/td\u003e\n\u003ctd\u003eIncreased blended cost per unit\u003c\/td\u003e\n\u003ctd\u003eOffsetting gross margin improvement in Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMCT in Comparative Study Cohort\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23%\u003c\/strong\u003e of cohort\u003c\/td\u003e\n\u003ctd\u003eCAMELOT study (Medicare beneficiaries)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic Yield vs. MCT (Zio LTCM)\u003c\/td\u003e\n\u003ctd\u003eHigher\u003c\/td\u003e\n\u003ctd\u003eZio LTCM had higher diagnostic encounter diagnosis than MCT (\u003cstrong\u003e27.1%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate. While MCT devices exist, iRhythm’s 14-day Zio AT offers a compelling alternative to traditional MCT devices.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Zio AT device provides continuous, uninterrupted recording for up to \u003cstrong\u003e14 days\u003c\/strong\u003e. The Zio monitor ECG device (next-gen Zio LTCM) was worn by over \u003cstrong\u003e1 million patients\u003c\/strong\u003e since its launch in late 2023, representing nearly \u003cstrong\u003e70%\u003c\/strong\u003e of iRhythm's LTCM registrations in the U.S. at that time. The company submitted a 510(k) for its new Zio MCT product in Q3 2025. \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Medium. Competitors can offer MCT, but Zio AT’s integration with the broader Zio ecosystem offers a differentiated experience.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProprietary hydrogel electrodes ensure an ECG signal with minimal artifact.\u003c\/li\u003e\n\u003cli\u003ePatented flexible, lightweight, water-resistant design.\u003c\/li\u003e\n\u003cli\u003ePatient-centered design translates into an astounding \u003cstrong\u003e98%\u003c\/strong\u003e patient compliance.\u003c\/li\u003e\n\u003cli\u003eHigh patient compliance enables \u003cstrong\u003e99%\u003c\/strong\u003e analyzable time.\u003c\/li\u003e\n\u003cli\u003eEnd-of-wear reports show \u003cstrong\u003e99%\u003c\/strong\u003e physician agreement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High. The company cites sustained demand for Zio AT as a key driver for raising its FY 2025 revenue guidance.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained demand for Zio AT was cited as a driver for raising FY 2025 revenue guidance to between \u003cstrong\u003e$735 million to $740 million\u003c\/strong\u003e, up from previous guidance. Q3 2025 revenue reached \u003cstrong\u003e$192.9 million\u003c\/strong\u003e, a \u003cstrong\u003e30.7%\u003c\/strong\u003e increase compared to Q3 2024, driven by sustained demand for Zio AT. The company raised its full-year 2025 Adjusted EBITDA margin guidance to approximately \u003cstrong\u003e8.25% to 8.75%\u003c\/strong\u003e of revenues. \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. New product features and clearances can be matched, but the current demand signals strength.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company received FDA 510(k) clearance for design modifications to the Zio AT device, with enhancements expected to be available in \u003cstrong\u003e2025\u003c\/strong\u003e. The company also submitted a 510(k) for its next-generation Zio MCT product in September 2025. New account growth contributed approximately \u003cstrong\u003e65%\u003c\/strong\u003e of year-over-year volume growth in Q1 2025. \u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: EHR Integration and Workflow Penetration\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Integration with Electronic Health Record (EHR) systems, like Epic Aura, drives utilization uplift of about \u003cstrong\u003e25%\u003c\/strong\u003e within six months of integration.\u003c\/p\u003e\n\u003cp\u003eThe value proposition is further quantified by the scale of adoption and efficiency gains:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOver \u003cstrong\u003e1.5 million\u003c\/strong\u003e all-time registrations for Zio services received through EHR-integrated customers.\u003c\/li\u003e\n\u003cli\u003eEstimated staff time costs saved by health systems are in the range of \u003cstrong\u003ehundreds of thousands of hours\u003c\/strong\u003e and \u003cstrong\u003emillions of dollars\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare. Deep, functional integration that demonstrably improves utilization is a high barrier to entry for competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. EHR integration is complex, requiring technical expertise, security clearances, and strong relationships with health systems. The collaboration with Epic through Aura is estimated to reduce integration time by up to \u003cstrong\u003e75%\u003c\/strong\u003e compared to traditional methods, indicating a significant technical hurdle for others.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The focus on integrating with 76 of the top 100 customers shows a clear strategy to embed the service into daily clinical practice.\u003c\/p\u003e\n\u003cp\u003eSpecific scale metrics related to the Epic ecosystem demonstrate organizational focus:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Top 100 Customers EHR Integrated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e76\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpic Aura Systems Live\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpic Aura Systems in Implementation\/Discussion\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration Time Reduction via Aura (Estimate)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e75%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandard HL7 Integration Time (Comparison)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12-week\u003c\/strong\u003e standard\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Once embedded in the EHR, switching costs for a health system become very high.\u003c\/p\u003e\n\u003cp\u003eKey quantitative achievements supporting the embedded nature of the solution include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Zio service registrations via EHR integration: Over \u003cstrong\u003e1,500,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential patient population impacted by Epic integration: Over \u003cstrong\u003e250 million\u003c\/strong\u003e patients in the U.S. with records in Epic.\u003c\/li\u003e\n\u003cli\u003eIntegration setup time reduction: From standard 12 weeks to ~3–6 weeks with the Turbocharger package.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiRhythm Technologies, Inc. (IRTC) - VRIO Analysis: International Commercial Footprint \u0026amp; Expansion\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational Commercial Footprint \u0026amp; Expansion\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eValue: Provides diversification away from the U.S. market and opens up new patient pools, with a commercial launch in Japan in \u003cstrong\u003eMay 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eRarity: Moderate. Having established commercial operations in \u003cstrong\u003esix\u003c\/strong\u003e markets outside the U.S. plus Japan is a good start.\u003c\/p\u003e\n\n\u003cp\u003eImitability: Medium. Regulatory hurdles and establishing local sales channels take time and capital, which iRhythm has already spent. The AI algorithm has \u003cstrong\u003ePMDA-approval\u003c\/strong\u003e in Japan.\u003c\/p\u003e\n\n\u003cp\u003eOrganization: High. The international expansion is a stated growth lever, showing management is allocating resources to this area. Full Year \u003cstrong\u003e2025\u003c\/strong\u003e revenue projection is between \u003cstrong\u003e$675 million to $685 million\u003c\/strong\u003e, with international expansion as a focus.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Advantage: Temporary. International growth is an ongoing process, but the established presence is a current advantage over pure domestic players.\u003c\/p\u003e\n\n\u003cp\u003eInternational Commercial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Markets (Ex-US)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAustria, Netherlands, Spain, Switzerland, UK, plus Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan Market Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.6 million\u003c\/strong\u003e tests\u003c\/td\u003e\n\u003ctd\u003ePrescribed annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZio Monitoring Duration\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e14 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCompared to \u003cstrong\u003e24 to 48 hours\u003c\/strong\u003e (Wired Holter) in Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Compliance (Japan)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported metric for Zio system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyzable Data Rate (Japan)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported metric for Zio system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUnrestricted cash, cash equivalents and marketable securities were \u003cstrong\u003e$535.6 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eFull Year \u003cstrong\u003e2024\u003c\/strong\u003e Revenue was \u003cstrong\u003e$591.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516189630613,"sku":"irtc-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/irtc-vrio-analysis.png?v=1740186292","url":"https:\/\/dcf-model.com\/fr\/products\/irtc-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}